Business
Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA®
Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA®.
About this update from Arno Therapeutics Inc
[{"type":"text","content":"\nFLEMINGTON, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company dedicated to the development of therapeutics for cancer and other life threatening diseases, today announced that it has determined to focus its onapristone development program on metastatic castration-resistant prostate cancer (CRPC) that has become resistant to ZYTIGA® (abiraterone acetate) therapy.  To support this milestone decision, Arno Therapeutics is pleased to announce the formation of a special Prostate Cancer Advisory Board.\nThe ongoing onapristone prostate cancer Phase II study is supported by the increasing scientific evidence for the role of the progesterone receptor (PR) pathway as a negative prognostic factor in men with advanced prostate cancer.  Published studies report a significant increase in progesterone blood levels and higher expression of PR by cancer cells in patients with CRPC who progress while being treated with ZYTIGA.  The ongoing Phase II study in CRPC is evaluating onapristone in combination with ZYTIGA in men who fail ZYTIGA alone. This multi-site trial, which is expected to enroll approximately 75 patients, is taking place in Europe, led by investigators from the Institute of Cancer Research, Royal Marsden Hospital in the UK with expansion to include sites in the United States.  The newly-formed Prostate Cancer Advisory Board at ARNO will be chaired by Stuart Holden, MD, a Clinical Professor of Urology, Spielberg Family Chair in Urologic Oncology Associate Director, and Institute of Urologic Oncology at the UCLA David Geffen School of Medicine. The additional members of the Advisory Board include:Gerhardt Attard MD, PhD, Cancer Research UK Clinician Scientist and Honorary Consultant, The Institute of Cancer Research and the Royal Marsden, Sutton, SurreySuzanne D. Conzen, MD, Professor of Medicine, The University of Chicago Medicine, Chicago, ILChristopher J. Logothetis, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TXPeter S. Nelson, MD, Professor School of Medicine University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WashingtonKenneth J. Pienta, MD, Donald S. Coffey Professor and Director of Research,...